Article

Nephrotoxicity of the BRAF-kinase inhibitor Vemurafenib is driven by off-target Ferrochelatase inhibition

2021-01-31

Abstract excerpt

A multitude of disease and therapy related factors drive the frequent development of renal disorders in cancer patients. Along with chemotherapy, the newer targeted therapeutics can also cause renal dysfunction through on and off-target mechanisms. Interestingly, among the small-molecule inhibitors approved for the treatment of cancers that harbor BRAF-kinase activating mutations, vemurafenib can trigger tubular d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1b8d33b3-4d8a-501f-83a4-9493b7fd6145
DOI: 10.1101/2021.01.29.428783

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Nephrotoxicity of the BRAF-kinase inhibitor Vemurafenib is driven by off-target Ferrochelatase inhibitionDOI 10.1101/2021.01.29.428783Read

Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition.Semantic proximity Read

New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma.Semantic proximity Read

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.Semantic proximity Read

EZH2 Suppresses Ferroptosis in Hepatocellular Carcinoma and Reduces Sorafenib Sensitivity Through Epigenetic Regulation of TFR2Semantic proximity Read

Proteomic Signatures of Vemurafenib Resistance in Canine Urothelial Carcinoma Harboring the BRAFV595E Mutation.Semantic proximity Read

Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.Semantic proximity Read

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.Semantic proximity Read

Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-RafV600E melanoma cells.Semantic proximity Read

A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.Semantic proximity Read

[Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease].Semantic proximity Read

TEAD inhibitor induced switch in energy metabolism drives human podocyte injury in vitroSemantic proximity Read

Binding to Albumin and Off-Target Toxicity Confound the Use of LRRC8/VRAC Channel Blockers in Cell Physiology AssaysSemantic proximity Read